UPDATE: U.S. oil prices settle nearly 25% higher; Trump expects a Saudi Arabia-Russia output cut
Today 3:14 PM ET (MarketWatch)

Oil futures rallied Thursday (http://www.marketwatch.com/story/oil-prices-surge-nearly-10-after-trump-says-russia-saudi-feud-can-be-resolved-2020-04-02), finding support after President Donald Trump tweeted (

Just spoke to my friend MBS (Crown Prince) of Saudi Arabia, who spoke with President Putin of Russia, & I expect & hope that they will be cutting back approximately 10 Million Barrels, and maybe substantially more which, if it happens, will be GREAT for the oil & gas industry!

— Donald J. Trump (@realDonaldTrump) April 2, 2020

.....Could be as high as 15 Million Barrels. Good (GREAT) news for everyone!

— Donald J. Trump (@realDonaldTrump) April 2, 2020

IN other words, the oil price debacle has been perceived as a huge negative for MMTIF and their AROMA units, but in reality it is a huge boast to demand for the units. The present sellers do no know this,imo.

I never thought we would get an opportunity to buy MMTIF shares below .04 cents but thanks to the perfect storm in the oil market of the last 3 weeks shares we have that opportunity again. And it is because of the same dumb sellers through CDEL as back in Nov, Dec, And Early Jan.

What they do not know is that this perfect storm that crashed oil prices is driving Oil and Gas companies to speed up their adoption of the Cloud Bases High Technology because of the tremendous benefits to the oil and gas companies in lowering their costs of production. So take advantage because the potential market for AROMA units will drive demand faster than expected over the rest of this year. All jmo !!!

IPIX share price sell down this AM is not unexpected. Gaps have to be filled and there is only one exception to that rule. And i will post it when that exception is valid for IPIX. I do believe it will be soon.

My hope for this meeting is that Trump and the oil companies decide to offer a deal to OPE plus the Russians. As trump likes to say "what the hell do they [oil companies] have to loose". The market as already cut their production so they could offer to cut production by a million barrels per day if both OPEC and Russia also cut production by one million barrels per day..... For six months....

(Bloomberg) -- Oil touched session highs then sold off abruptly in the final half hour before settlement on Wednesday after news that President Trump is set to meet with top executives at the nation’s largest oil companies to discuss measures to help the industry.

The meeting, set for Friday, comes after a flurry of U.S.-driven diplomacy, with Trump speaking with both Russia and Saudi leaders to broker a deal, though the former OPEC+ allies have no plans to speak to each other, the Kremlin said.

Rest of the story.... This headline is false as the meeting is Friday and maybe Saturday:

https://www.rigzone.com/news/wire/trump_meeting_with_drillers_failed_to_boost_oil_futures-01-apr-2020-161610-article/

Attention IPIX management...nebulized drug!!!!

Ampio Pharma Highlights FDA Application For Ampion To Treat Coronavirus-Induced Acute Respiratory Distress Syndrome Featured In FOX News Video
Today 9:11 AM ET (Benzinga)

Ampio Pharmaceuticals, Inc. (NYSE:AMPE),a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions announced today that it was featured on a FOX segment titled, "Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug," reported by an affiliated television station in Denver, Colorado. The primary cause of death associated with SARS-Cov-2 ("COVID-19") infection is Acute Respiratory Distress Syndrome ("ARDS"), and there are no approved treatments for ARDS or COVID-19. The segment featured the Company's application to the FDA to study the treatment of COVID-19 induced ARDS with nebulized Ampion.

To view the FOX video segment in its entirety please visit the link below. Additional information about the potential suitability of the anti-inflammatory properties of Ampion being used for this clinical indication (ARDS) is included in a companion white paper summary titled, "Rationale and scientific evidence for the use of Ampion in the treatment of Acute Respiratory Distress Syndrome secondary to SARS-COV-2," provided in the link below.

https://kdvr.com/news/coronavirus/englewood-pharmaceutical-company-looking-to-treat-covid-19-patients-with-anti-inflammatory-drug/


https://ampiopharma.com/wp-content/uploads/2020/04/01-Apr-2020-Ampion-SARS-COV-2-and-ARDS-Flyer_v4.pdf
Michael Macaluso, Ampio CEO, noted "The Company is exploring options that may enable the completion of the AP-013 study, our Phase 3 clinical trial for the treatment of severe osteoarthritis of the knee, during this COVID-19 pandemic. Simultaneously, we have directed our R&D efforts to explore the possible application of the immunomodulatory and anti-inflammatory properties of Ampion in the most severe and lethal complication of the COVID-19 infected patients: ARDS. The FDA has been very responsive, and the Company is grateful for the Agency's efforts as we work together to study the potential benefits of Ampion in this population."

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

FDA Pathways:

Pathways specific to COVID-19
Coronavirus Treatment Acceleration Program
What it is: A “special emergency program” intended to accelerate the review of therapies intended to treat, cure or prevent COVID-19. The review program “uses every available method to move new treatments to patients as quickly as possible.” The pathway combines many elements from other review programs and pathways listed below, such as rolling review, accelerated timelines, hands-on support from FDA review staff and more.

The pathway is intended to begin early in clinical development, with the FDA providing “ultra-rapid, interactive input on most development plans,” review of clinical protocols within 24 hours of submission, review of single patient expanded access requests “generally within 3 hours” and working collaboratively to conduct quality assessments and transfer manufacturing “to avoid supply disruption.”

What it’s generally used for: The acceleration of medical therapies intended to treat, cure or prevent COVID-19.
Limitations: As with other review acceleration methods, the FDA’s ultra-rapid review will only be as useful as the ability of a company to move quickly to establish a manufacturing site, generate and analyze data, and make submissions. The ultra-rapid reviews may also miss some critical safety or efficacy issues that might have been discovered through more extensive analysis.
How it could be used in the context of COVID-19: Expect all COVID-19 products to receive an all-hands review by the FDA, with some product reviews taking place in days instead of months. The FDA says it plans to “continue to enhance and expand CTAP,” so further changes are expected soon.

Further reading: Coronavirus Treatment Acceleration Program
Also known as: CTAP
Regulatory/Legal authority: N/A. More akin to a pilot program, and not established under regulation or statute.

The president is pressuring the FDA to issue emergency use authorization for favipiravir, a flu drug that showed glimpses of success in China but remains unproven and carries a list of worrying side effects. The push comes after a week-plus in which the White House touted a potentially effective but unproven malaria medication despite the concerns of scientific advisors such as NIAID director Anthony Fauci. And Trump ally

We all know and can agree that the Oil and gas industry is in a state of turmoil because of the Covi19 shutdowns in much of the world plus the little fuss between Saudi Arabia and Russia over the quotas for oil production, This has lead to quite dramatic cutbacks by most of the Oil companies on Capital spending plans for this year. So that has rebounded into the MMTIF shares market with light selling. and the shares have pulled back to the previous .04 cents/share breakout which should now be a pretty good support zone.

The most overriding question now is what does all this mean for MMTIF share price going forward. Glad you ask because here is what think all this mess in the oil market means. The most sensible action for the big oil companies to take going forward are as follows:

1] Get as efficient as possible and that means speeding up the adoption of the cloud based high technology products to reduce downtime and solve E and P problems faster and cut labor and lab costs.
2] Find ways to get more oil out of each well by using the Aroma technology to solve bottlenecks and problems. This is much less expensive than drilling wells.

And the above means that the current problems may indeed be a catalyst to bring more big oil companies to MMTIF as customers for the Aroma products. All JMO!!!!

farell90......Yes B could be in this labs wide array of drugs to be tested, but it is not the source of today's press release by IPIX. That test was done at a RBL lab [U.S. Regional BioContainment Lab] One of 13 scattered around the country with most if not all being affiliated with Universities.

The Lab where Mr. Davey works is Boston University’s National Emerging Infectious Diseases Laboratories (NEIDL).

In my opinion, the RBL working with IPIX may be the RBL connected with James Mason University in Va. But that is just a guess based on a couple of clues.

https://www.niaid.nih.gov/research/biocontainment-research-facilities

We will know more when Alan post the daily short report, but it sure looked like MFO selling today. JMO!!!

Dr Jerry.....IMO, that is the best combination of drugs to knockout Covid19. But i would try it with Plaquenil and just Brilacidin so there would be a comparison with Plaquenil plus azithromycin in the present NY trial.

LongMMTI.... I do not think this is what Romgaz and MMTIF is working on for Romgaz's operation. I do think MMTIF could develop some flow sensor to be used with this Emerson system. But that is JMO!!!!

https://endpts.com/have-a-new-drug-that-promises-to-fight-covid-19-the-fda-will-see-you-now/

DrBones...I would bet the RBL has control of any coming news and did you see this: From HolesInMyPocket

https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap

williamssc....I agree. There is no need to send an email announcement about an announcement. However i do not expect an announcement today unless things are moving much faster than i think. I think the announcement to come will be about Human Trials and come from the government. Then our wall builder will have to construct several walls at ever increasing prices.

HIMP.... you are asking the correct questions. imo!!! Below is the original wording of the press release about the contract with the RBL:

"Under terms of the agreement, scientific research partners at the RBL plan to evaluate Brilacidin’s potential antiviral and anti-inflammatory properties in the context of viral infections, including inhibition of SARS-CoV-2, the virus responsible for COVID-19. Mechanism of action studies of Brilacidin, along with assessing possible synergistic effects with other antivirals, are also planned. It is anticipated these tests might be completed within several weeks of the RBL’s receipt of Brilacidin."

This is the one i am most interested in knowing about:

"along with assessing possible synergistic effects with other antivirals, are also planned."

Did they test it with Hydroxychloroquine???

HIMP.... you are asking the correct questions. imo!!!

That is because i am correct on this one.

Just to make myself clearly understood, i am positive about today's positive email. And i think the word parsing is somewhat off base. JMO!!!

Todays email from IPIX:

"The Company was informed late Monday by researchers at the RBL that preliminary testing has been completed and to expect the results as early as today. Subsequently, the results will be released to the public."

The word i noted was "Subsequently" not so much the word "will", but together they are powerful. JMO!!!

FROM AI: Kosmos and Tullow hardest hit by coronavirus

Oil and gas firms are watching in dismay as oil prices drop because of the global coronavirus pandemic (Covid-19). While most majors have large cash reserves at their disposal to weather the storm, two leading names in African oil exploration, [...] (645 words)

farrell90...I agree, It is individual Immune System differences, IMO. Right in B wheelhouse!!

Italy finally gets some good news:

4050 new cases and 812 new deaths in Italy. Total cases surpass 100,000 [source]

green Lowest number of new cases in the last 13 days (since March 17)
green Highest number of new recoveries (1,590) since the beginning of the epidemic

I sure am glad i am not Bi-polar. Terrible disease, but not as bad as covid19....on second thought it might be worse because covid19 only lasts for 2-4 weeks.

Would someone please cut and past and send to Leo this FDA limited approval at the request of BARDA; so that Leo could push for B. to be added in this or some other trial coming up. In my opinion, hydroxychloroquine , ZPAC, and Brilacidin could be the knock out punch for covid19.

I wonder....Emerson Introduces New Data Visualization Software for Flow Measurement
Monday, March 30, 2020

Micro Motion ProcessViz software provides an easy-to-use graphical view of data from Micro Motion Coriolis flow meters

March 29, 2020 — Emerson has released Micro Motion ProcessViz™, a standalone, cost-effective software solution for flow meter process data visualization. Having an instant visualization of raw process data translates into direct actionable information, helping plant operators in the chemical, food and beverage, and oil and gas industry reduce the time needed to identify a problem in the flow process. Ultimately, this can potentially save a facility money by reducing the need for stoppages or shutdowns to trace the source of a problem.

The new software supports the Micro Motion™ Coriolis transmitters with data historian output capabilities such as the 5700 and 4200 models and provides a snapshot of a moment in time in the flow process. A technician or plant manager won’t need to manipulate data to see what is happening in the flow. The data is available in a usable format that allows the user to identify and analyze process issues.

“We created ProcessViz after our customers saw us using it to diagnose their flow problems,” said Ron Fleissman, software product manager for Emerson’s Automation Solutions business. “We received so many requests for this software that we realized there was a need in the market for a tool that would make it easier for our customers to diagnose process issues that might be caused by changes in the flow, thereby saving them time and money.”

For more information on Micro Motion ProcessViz, go to www.Emerson.com/MicroMotionProcessViz.

CallMeCrazy....Yep here is what BARDA said:

BARDA, the HHS department tasked with preparedness and response, submitted the EUA request. The FDA noted that this authorization is intended to benefit adult and teen patients who are hospitalized and can’t participate in the handful of clinical trials underway in the US.

Based upon limited in-vitro and anecdotal clinical data in case series, chloroquine phosphate and hydroxychloroquine sulfate are currently recommended for treatment of hospitalized COVID-19 patients in several countries, and a number of national guidelines report incorporating recommendations regarding use of chloroquine phosphate or hydroxychloroquine sulfate in the setting of COVID-19. […]

Based on the totality of scientific evidence available to FDA, it is reasonable to believe that chloroquine phosphate and hydroxychloroquine sulfate may be effective in treatingCOVID-19, and that, when used under the conditions described in this authorization, the known and potential benefits of chloroquine phosphate and hydroxychloroquinesulfate when used to treat COVID-19 outweigh the known and potential risks of suchproducts.

Now i just hope someone in the various Gov. Agencies has the good sense to start a Trial using Brilacidin with hydroxychloroquine. That could bw a knockpunch treatment for covid19, imo.

Summary From: https://tinyurl.com/qla297j

Like all producers, Chevron faces a two-headed hydra of much lower global demand and increased oversupply that has forced oil prices down from $60/barrel recently to $20/barrel now.

Chevron’s dividend is $5.16/share for a yield of 7.5%; it is cutting its capital budget to prioritize its dividend. The company's market capitalization is $129.3 billion.

Because of its good balance sheet, budgeting pivot, and international operations, Chevron is in better shape to withstand the oil price downturn than smaller, U.S.-only producers.

Looking for more stock ideas like this one? Get them exclusively at Econ-Based Energy Investing. Get started today »

LongMMTI.....Thanks for the valid points in your post. The bottom line on this technology is the huge benefit provided to the oil and gas companies in lowering their costs by adding incremental production from producing wells. It is much less costly to add to the recovery of more of the oil in the ground thus lowering the cost/per barrel of producing oil than it is to go find a new field. And the next post touches on Chevron strengths.

cpac...Always the smart A. The answer is ZERO to both. But that will change and the only way for anyone to make any money on this stock is to believe the past is not prologue for MMTIF. And i do believe this time is different for all the reasons i have posted about in the last couple of years. But here now is a different reason and that is the oil and gas companies need technology to cut expenses and increase income. Location is still important but ROI is now more important and the AROMA units deliver superb ROI or cost vs benefit.

Vela700....The product of that joint venture worked very well, but Northeast Utilities dropped out and sort of left MMTIF holding the bag [over $2 million write off]. Do you know why they pulled back and dropped the partnership???? If so enlighten us.

It was public when Offer bought control.

It was public when Offer bought control.

EVE4.....Right ON. Thanks!

Oh i do every day. And i see an aging male who real early in his life learned to do my best and that my word was my bond. What is your personal creed?

Empiricst1....Thanks for this information....Exactly what i was posting about earlier:

"Conclusion
Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin."


MY OPINION BELOW:

And hydroxychloroquine plus Brilacidin will be even more effective to the point of being a combination that could prevent Covid19 after exposure to the virus. JMO!!!

JTORENCE....What i posted is true. What you posted is not. Please get up to speed as there is a vast difference between the Daily Short Interest report and the the real short interest report. It was the Daily Short Interest report i was referring to in my post to DrBones. And the day in question had 69% of the daily volume THAT DAY reported as short sales most of which were DAILY SHORT sales done by Market Makers to facilitate a client's sale order. And those sales were covered during the trading day or shortly there after by a buy by those same market makers from their clients to cover the day trade short sale. That is the way the market works in the OTC market and most people do not understand this vital function at all.

The above method HAS to be done by the MMs in order to conduct a viable market without taking on a huge risk of their own capital. It is the number one most misunderstood factor of the operating of the OTC stock market by individual investors. That misunderstanding is the source of innumerable posts about MM manipulation. On the subject of posts about those manipulating Market Makers they are a giant waste of broadband and a waste of time to read and consider. All JMO!!!!